Shandong Xinhua Pharmaceutical Company Limited has issued a circular detailing the agenda for its 2025 Annual General Meeting, scheduled for 2:00 p.m. on 26 June 2026 at the company’s headquarters in Zibo, Shandong Province.
Key resolutions to be tabled include:
• 2025 Performance Review: Shareholders will vote on the annual report, Board report and audited financial statements for the year ended 31 December 2025.
• Profit Distribution: The profit-distribution plan for 2025 will be submitted for approval. Specific payout figures were not disclosed in the circular.
• Auditor Mandate: The Board proposes to re-appoint Grant Thornton Zhitong Certified Public Accountants LLP for the 2026 financial year at an aggregate fee of RMB 0.76 million, comprising RMB 0.65 million for the annual audit and RMB 0.11 million for internal-control assurance.
• Director Compensation: The meeting will authorise the Board to determine 2026 remuneration for directors in line with the company’s remuneration policy.
• Remuneration Management System: Shareholders will consider a new “Remuneration Management System for Directors and Senior Executives,” approved by the Board on 28 April 2026.
• Articles of Association Amendments: 1) Registered address to change to “No. 1 Lutai Ave., Hi-tech District, Zibo City, Shandong Province, PRC.” 2) Share-capital table to be updated after the exercise of 6.91 million A-share options on 14 January 2026, lifting total issued shares from 689.78 million to 696.68 million. 3) Alignment with Shandong Province’s latest governance guidelines, including codifying the “two-way entry and cross-appointment” mechanism between Party and corporate bodies.
Poll Voting & Record Date: The share register closes from 18 June to 26 June 2026. H-shareholders must lodge transfers by 4:30 p.m. on 17 June 2026 to qualify for attendance and voting. All AGM resolutions will be decided by poll.
Proxy Arrangements: Shareholders unable to attend may submit proxy forms no later than 24 hours before the meeting.
The Board recommends voting in favour of all proposed resolutions, stating that the amendments align with PRC company law, listing rules and internal governance needs.
Comments